

TG THERAPEUTICS, INC.  
Form 8-K  
December 10, 2012

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **December 10, 2012**

**TG Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

**001-32639**

**36-3898269**

(State or Other Jurisdiction (Commission File Number)

(IRS Employer Identification No.)

of Incorporation)

**787 Seventh Ave, 48<sup>th</sup> Floor**

**New York, New York 10019**

(Address of Principal Executive Offices)

**(212) 554-4484**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
-

**Item 8.01. Other Events**

On December 10, 2012, TG Therapeutics, Inc. (the “Company”) issued a press release announcing highlights from the TG-1101 and TGR-1202 posters presented at the 54<sup>th</sup> Annual Meeting of the American Society of Hematology (“ASH”), held this past weekend, at the Georgia World Congress Center in Atlanta, Georgia. A copy of the press release, which outlines portions of the ASH conference materials, is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 9.01 Financial Statements And Exhibits.**

(d)Exhibits.

99.1 Press release issued by the Company on December 10, 2012.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TG Therapeutics, Inc.**

(Registrant)

Date: December 10, 2012

By: /s/ Sean A. Power

Sean A. Power

Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number	Description
-------------------	-------------

99.1	Press release issued by TG Therapeutics, Inc. on December 10, 2012.
------	---